Ratings Laboratorio Farmaceutico Erfo S.p.A.

Equities

ERFO

IT0005497885

Market Closed - Borsa Italiana Other stock markets 09:14:59 28/06/2024 pm IST			5-day change	1st Jan Change
1.16 ^EUR	-1.69%		+5.45%	-11.45%

04/06	Erfo, MIMIT grant facilities for Plants project.	AN
27/05	Laboratorio Farmaceutico Erfo buys 13,000 shares	AN

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The company has a low valuation given the cash flows generated by its activity.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
LABORATORIO FARMACEUTICO ERFO S.P.A.	-11.45%	1.07Cr	-
ELI LILLY AND COMPANY	+55.32%	82TCr	C+
JOHNSON & JOHNSON	-6.75%	35TCr	C+
MERCK & CO., INC.	+13.56%	31TCr	B-
ABBVIE INC.	+10.68%	30TCr	C+
ASTRAZENECA PLC	+16.57%	24TCr	B+
ROCHE HOLDING AG	+2.04%	22TCr	A+
NOVARTIS AG	+13.31%	22TCr	B-
AMGEN INC.	+8.48%	17TCr	C+
PFIZER, INC.	-2.81%	16TCr	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes